Benjamin Oakes’ Scribe Therapeutics is developing specialized Crispr proteins to tackle a wide range of diseases–and it’s garnered deals with Big Pharma potentially worth over $4 billion.
Category: biotech/medical – Page 781
Pigs might help solve the organ transplant crisis if researchers can make the process safe enough. Preventing rejection in brain-dead subjects is a step toward that goal.
GTB-3550 is the company’s first TriKE® product candidate that was evaluated in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies. Phase 1 clinical trials were shown to be both safe and well-tolerated, as well as proving the molecule’s clinical concept and providing a framework for future product candidates.
GTB-3650 is a second-generation protein developed to treat AML and MDS. It has replaced GTB-3550 and utilizes camelid nanobody technology. GTB3650 has successfully completed pre-clinical trials and is in the good manufacturing process (GMP) stage, which is usually the last developmental milestone before progressing into phase 1 clinical trials.
DURHAM – A big licensing deal potentially worth hundreds of millions of dollars with an Austrlia-based company at the same time also has triggered what Precision Biosciences calls a “right-sized” organization of the company.
“Prior to the announcement, we had 190 employees, with 110 going forward with Precision. Most of the 80 employees went with Imugene, with the remainder parting ways with a reduction in force,” Mei Burris, director of investor relations and finance for the company,” told WRAL TechWire.
What “right-sized” means was not immediately explained in the company’s announcement Tuesday night after the markets closed. The company’s stock is trading at under $1 and it lost $12 million in its most recent quarter ending June 30.
A study that peered into live mouse brains suggests for nearly 70 years we’ve been targeting the wrong neurons in our design of antipsychotic drugs.
Untangling the vast web of brain cells and determining how drugs work upon them is a tough task. Using a miniature microscope and fluorescent tags, a team of researchers led by Northwestern University neuroscientist Seongsik Yun discovered that effective antipsychotic drugs cling to a different type of brain cell than scientists originally thought.
Just like research suggesting depression might not be a chemical imbalance in serotonin levels, our understanding of schizophrenia treatments may need a rethink if widely-used antipsychotics are targeting different neurons than expected.
Canadian researchers at the University of Montreal have successfully recreated and mathematically confirmed two molecular languages at the origin of life.
Their groundbreaking findings, recently published in the Journal of American Chemical Society, pave the way for advancements in nanotechnologies, offering potential in areas like biosensing, drug delivery, and molecular imaging.
Living organisms are made up of billions of nanomachines and nanostructures that communicate to create higher-order entities able to do many essential things, such as moving, thinking, surviving, and reproducing.
Genome-wide association analyses of magnetic resonance imaging data describe the genetic architecture of 13 cortical phenotypes at both global and regional levels, implicating neurodevelopmental and constrained genes.
A new method allows large quantities of muscle stem cells to be safely obtained in cell culture. This provides a potential for treating patients with muscle diseases – and for those who would like to eat meat, but don’t want to kill animals.
Elon Musk delves into the groundbreaking potential of Neuralink, a revolutionary venture aimed at interfacing with the human brain to tackle an array of brain-related disorders. Musk envisions a future where Neuralink’s advancements lead to the resolution of conditions like autism, schizophrenia, memory loss, and even spinal cord injuries.
Elon Musk discusses the transformative power of Neuralink, highlighting its role in restoring motor control after spinal cord injuries, revitalizing brain function post-stroke, and combating genetically or trauma-induced brain diseases. Musk’s compelling insights reveal how interfacing with neurons at an intricate level can pave the way for repairing and enhancing brain circuits using cutting-edge technology.
Discover the three-layer framework Musk envisions: the primary layer akin to the limbic system, the more intelligent cortex as the secondary layer, and the potential tertiary layer where digital superintelligence might exist. Musk’s thought-provoking perspective raises optimism about the coexistence of a digital superintelligence with the human brain, fostering a harmonious relationship between these layers of consciousness.
Elon Musk emphasises the urgency of Neuralink’s mission, stressing the importance of developing a human brain interface before the advent of digital superintelligence and the elusive singularity. By doing so, he believes we can mitigate existential risks and ensure a stable future for humanity and consciousness as we navigate the uncharted territories of technological evolution.
For more insights, visit EM360tech.com:
https://em360tech.com/tech-news.
#AI #superintelligence #machinelearning.
A new technique mimics the normal reprogramming process in early embryonic development to essentially wipe a cell’s memory, making it similar to a stem cell.